In the clinics, resistance to targeted therapy may depend on the drug-resistant phenotype of preexisting tumor cell subpopulations (intrinsic resistance) or occur via de novo mutations that render cancer cells permanently refractory to BRAF/MEKi treatment (acquired resistance) [3, 5]. The gene discussed is BRAF; the disease is neoplasm.